Angus brings over 20 years Drug Development and Business Development experience to DDF
Angus joined DDF in July 2018 as CEO
Prior to joining the DDF, Angus worked at Celgene for almost 12 years. He started at Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters. In 2008, Angus moved to London as Head of Europe RA for 3 years. Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, in 2011, and most recently as Corporate VP of Business Development, where he completed multiple innovative deals spanning discovery and late stage clinical assets, and in tandem built the Alliance Management function, managing over 60 collaborations and investments with pharmaceutical and biotech partners. Before leaving, Angus served as Corporate VP of Business Development, leading the BD team running the transactions. Angus previously worked at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US Food and Drug Administration.
Angus received his undergraduate degree from the University of Richmond, then his Ph.D. in Anatomy & Immunology from the Medical College of Virginia and completed his post-doctoral training at the National Cancer Institute in Bethesda.
Outside of SV
Angus sits on the Board of MaRS Innovation
Dementia Discovery Fund